



HVTN 405/HPTN 1901 Study fact sheet

What is the HVTN 405/HPTN 1901 study about?

HVTN 405/HPTN 1901 will describe immune responses in study participants with a history of recovering from SARS-CoV-2 infection. A main aim of HVTN 405/HPTN 1901 is to develop antibody assays that can be reliably used to detect SARS-CoV-2 infection in vaccine and monoclonal antibody studies to prevent COVID-19. This information will be critical in illuminating the path to the development and testing of safe and effective vaccine and antibody interventions to prevent COVID-19.

Where will the study take place?

Study teams seek to enroll approximately 400 study participants at clinical trial sites across North and South America.

Which clinical trial sites will participate in HVTN 405/HPTN 1901?

Table 1: List of clinical trial sites in the US participating in HVTN 405/HPTN 1901

City /Town	Clinical Research Site	City /Town	Clinical Research Site
Atlanta	Hope Clinic at Emory University	Los Angeles	UCLA CARE Center
	Ponce de Leon Center		
Baltimore	Johns Hopkins University	Nashville	Vanderbilt HIV Vaccine Program
Birmingham	Alabama Vaccine Research Clinic at UAB	Newark	Rutgers New Jersey Medical School Clinical Research Center
Boston	Brigham and Women's Hospital	New Orleans	Adolescent Trials Unit
	Fenway Community Health Center	Philadelphia	University of Pennsylvania Prevention
Chapel Hill	University of North Carolina -Chapel Hill	Rochester	University of Rochester Victory Alliance
Chicago	Adolescent & Young Adult Research (AYAR) at the CORE Center	San Francisco	Bridge HIV
Cleveland	Case Western Reserve/University Hospitals	Seattle	Seattle Vaccine Trials Unit
New York	Bronx Prevention Center	Washington DC	George Washington University
	Harlem Prevention Center		
	New York Blood Center		
	Columbia Physicians & Surgeons Research Unit		

Table 2: List of clinical trial sites in South America participating in HVTN 405/HPTN 1901

City /Town	Clinical Research Site	City /Town	Clinical Research Site
Lima	IMPACTA-Barranco	Iquitos	Asociacion Civil Selva Amazonica
	IMPACTA-San Miguel		
	San Marcos/CITBM		
	Via Libre		

How will study participants contribute to HVTN 405/HPTN 1901?

- Participants will attend one required clinic visit and will have the option to attend additional clinic visits two, four and twelve months after the initial visit.
- Each visit includes a questionnaire, blood draw and optional nasal sampling.
- Individuals who have not fully recovered from their infection (i.e., still have symptoms or had a positive test within the preceding two weeks) will not be enrolled.

Why is it important to conduct HVTN 405/HPTN 1901?

- SARS-CoV-2 is the most infectious of three coronaviruses that have caused recent epidemics resulting in significant morbidity and mortality in humans in the last 20 years.
- This study will describe the body’s natural immune responses to SARS-CoV-2, thus illuminating the path to the development and testing of a safe and effective vaccine.
- Vaccines will not only be essential to prevent new infections and reduce morbidity and mortality, but they will also aid in a return to a thriving social and economic global infrastructure.

1. Yang CY, Wang J. A mathematical model for the novel coronavirus epidemic in Wuhan, China. *Math Biosci Eng.* 2020;17(3):2708-24.

Which organizations are conducting HVTN 405/HPTN 1901?

- The National Institute of Allergy and Infectious Diseases (NIAID) of the US National Institutes of Health (NIH) is funding the study.
- The NIAID-funded HIV Vaccine Trials Network (HVTN) and HIV Prevention Trials Network (HPTN) are coordinating the study with their participating clinical research sites.
- Interested individuals can email info@hvtn.org for more information.

Will the HVTN continue its pursuit for a safe and globally effective preventive HIV vaccine?

- The HVTN remains committed to the global response to help end HIV by working with all communities, in-country partners, funders, and the scientific community to find a safe and globally effective preventive HIV vaccine.
- The HVTN and HPTN are leaders and scientific collaborators in interdisciplinary studies and maintain a global network of clinical trial sites, in addition to their Laboratory Programs and Statistical and Data Management Centers.
- The HVTN and HPTN will use this infrastructure to conduct studies and contribute to the global response to COVID-19. In addition, lessons learned from existing HIV vaccine and monoclonal antibody trials will be applied to the research to combat COVID-19, and new information from COVID-19 studies may also apply to ongoing research to prevent HIV and other infectious diseases.